Separate terms with OR to return results that match either term.
 
Clear All

10,000 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) (Ascending) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
25021-0222-04 25021-0222 Docetaxel Docetaxel 20.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous July 1, 2013 March 31, 2017 No Longer Used
25021-0222-07 25021-0222 Docetaxel Docetaxel 20.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous July 1, 2013 March 31, 2017 No Longer Used
25021-0223-20 25021-0223 Cytarabine Cytarabine 100.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intrathecal, Intravenous, Subcutaneous June 1, 2023 In Use
25021-0226-10 25021-0226 Arsenic Trioxide Arsenic Trioxide 1.0 mg/mL Chemotherapy Miscellaneous Agent PML/RARa Intravenous Feb. 15, 2023 In Use
25021-0227-06 25021-0227 Arsenic Trioxide Arsenic Trioxide 2.0 mg/mL Chemotherapy Miscellaneous Agent PML/RARa Intravenous Feb. 15, 2023 In Use
25021-0229-05 25021-0229 Cytarabine Cytarabine 20.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intrathecal, Intravenous, Subcutaneous June 1, 2023 In Use
25021-0230-02 25021-0230 Irinotecan Hydrochloride Irinotecan Hydrochloride 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Aug. 15, 2014 In Use
25021-0230-05 25021-0230 Irinotecan Hydrochloride Irinotecan Hydrochloride 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Aug. 15, 2014 In Use
25021-0231-20 25021-0231 Decitabine Decitabine 50.0 mg/10mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Aug. 15, 2018 No Longer Used
25021-0233-10 25021-0233 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Sept. 15, 2014 In Use
25021-0233-20 25021-0233 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Sept. 15, 2014 In Use
25021-0234-10 25021-0234 Gemcitabine Hydrochloride gemcitabine 200.0 mg/5mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Dec. 29, 2014 In Use
25021-0235-50 25021-0235 Gemcitabine Hydrochloride Gemcitabine 1.0 g/25mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Dec. 29, 2014 In Use
25021-0235-51 25021-0235 Gemcitabine Hydrochloride Gemcitabine 1.0 g/25mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Dec. 15, 2022 In Use
25021-0236-04 25021-0236 Topotecan Topotecan 1.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Dec. 15, 2014 Jan. 31, 2021 No Longer Used
25021-0237-06 25021-0237 Fludarabine phosphate Fludarabine phosphate 25.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Dec. 15, 2014 June 30, 2019 In Use
25021-0239-05 25021-0239 gemcitabine Gemcitabine 38.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Jan. 15, 2019 Sept. 30, 2020 No Longer Used
25021-0239-26 25021-0239 gemcitabine Gemcitabine 38.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Jan. 15, 2019 Feb. 28, 2021 No Longer Used
25021-0239-52 25021-0239 gemcitabine Gemcitabine 38.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Jan. 15, 2019 Aug. 31, 2020 No Longer Used
25021-0241-10 25021-0241 Busulfan Busulfan 6.0 mg/mL Chemotherapy Alkylating Agent Alkylsulfonate Intravenous May 15, 2017 In Use
25021-0242-02 25021-0242 Fludarabine phosphate Fludarabine phosphate 25.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Oct. 15, 2016 In Use
25021-0244-10 25021-0244 BORTEZOMIB BORTEZOMIB 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 1, 2022 In Use
25021-0245-01 25021-0245 Docetaxel Anhydrous Docetaxel 20.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Sept. 15, 2017 In Use
25021-0245-04 25021-0245 Docetaxel Anhydrous Docetaxel 20.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Sept. 15, 2017 In Use
25021-0246-02 25021-0246 Thiotepa Thiotepa 15.0 mg/1.5mL Chemotherapy Alkylating Agent Nitrogen Mustard /Ethylenimine Intracavitary, Intravenous, Intravesical June 15, 2018 In Use
25021-0248-51 25021-0248 Cyclophosphamide Cyclophosphamide 1.0 g/50mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Jan. 15, 2024 In Use
25021-0249-51 25021-0249 Cyclophosphamide Cyclophosphamide 2.0 g/100mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Jan. 15, 2024 In Use
25021-0250-20 25021-0250 Mitomycin Mitomycin 5.0 mg/10mL Chemotherapy Antitumor Antibiotic Alkylating Agent/ Mitomycin Intravenous June 15, 2023 In Use
25021-0251-50 25021-0251 Mitomycin Mitomycin 20.0 mg/40mL Chemotherapy Antitumor Antibiotic Alkylating Agent/ Mitomycin Intravenous June 15, 2023 In Use
25021-0252-51 25021-0252 Mitomycin Mitomycin 40.0 mg/80mL Chemotherapy Antitumor Antibiotic Alkylating Agent/ Mitomycin Intravenous June 15, 2023 In Use
25021-0253-50 25021-0253 Cisplatin Cisplatin 1.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous July 1, 2023 In Use
25021-0253-51 25021-0253 Cisplatin Cisplatin 1.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous July 1, 2023 In Use
25021-0254-08 25021-0254 Docetaxel Anhydrous Docetaxel 10.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Aug. 1, 2023 In Use
25021-0254-16 25021-0254 Docetaxel Anhydrous Docetaxel 10.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Aug. 1, 2023 In Use
25021-0255-05 25021-0255 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Feb. 1, 2024 In Use
25021-0255-17 25021-0255 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Feb. 1, 2024 In Use
25021-0255-50 25021-0255 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Feb. 1, 2024 In Use
25021-0451-01 25021-0451 Octreotide Acetate Octreotide Acetate 50.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Dec. 15, 2013 In Use
25021-0452-01 25021-0452 Octreotide Acetate Octreotide Acetate 100.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Dec. 15, 2013 Jan. 31, 2023 In Use
25021-0453-01 25021-0453 Octreotide Acetate Octreotide Acetate 500.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Dec. 15, 2013 Feb. 28, 2023 In Use
25021-0454-05 25021-0454 Octreotide Acetate Octreotide Acetate 200.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Dec. 15, 2013 March 31, 2021 In Use
25021-0455-05 25021-0455 Octreotide Acetate Octreotide Acetate 1000.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Dec. 15, 2013 Feb. 29, 2020 In Use
25021-0462-74 25021-0462 fulvestrant fulvestrant 50.0 mg/mL Hormonal Therapy Estrogen Receptor Antagonist Intramuscular Aug. 1, 2019 April 30, 2023 In Use
25021-0463-01 25021-0463 Octreotide acetate Octreotide Acetate 50.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous April 15, 2023 In Use
25021-0464-01 25021-0464 Octreotide acetate Octreotide Acetate 100.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous April 15, 2023 In Use
25021-0465-01 25021-0465 Octreotide acetate Octreotide Acetate 500.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous April 15, 2023 In Use
25021-0466-05 25021-0466 Octreotide acetate Octreotide Acetate 200.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous April 15, 2023 In Use
25021-0467-05 25021-0467 Octreotide acetate Octreotide Acetate 1000.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous April 15, 2023 In Use
25021-0777-02 25021-0777 ondansetron hydrochloride Ondansetron 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Aug. 30, 2012 In Use
25021-0778-01 25021-0778 Granisetron Hydrochloride Granisetron Hydrochloride 0.1 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Dec. 1, 2010 Feb. 1, 2017 No Longer Used

Found 10,000 results in 10 millisecondsExport these results